人混合原代肝細胞（hp2heps）為藥物試驗和藥物開發(fā)提供了理想的培養(yǎng)模型。HP2-10人混合原代肝細胞含有來自10個不同供體的冷凍保存肝細胞，只冷凍了一次。混合肝細胞提供了必要的遺傳多樣性，以保證試驗化合物相對于代表群體的代謝特征具有更高的可靠性和可預測性?；旌细渭毎ㄟ^消除獲得基于群體的數(shù)據(jù)所需的冗余實驗來增加實驗控制并降低成本。每個批次都經(jīng)歷了一個單獨的冷凍循環(huán)，以確保最大限度的肝細胞活力和供體之間的一致性。細胞特征：每個供者的肝細胞分離純化后立即冷凍保存?；旌系挠?0到20個捐贈者。每一個供體都由一個統(tǒng)計上顯著的細胞數(shù)來表示。有廣泛的質(zhì)量控制提供生存能力和酶活性的特征，從個人捐助者到整個庫。AcceGen保證性能和質(zhì)量，提供捐贈者信息。

Human Pooled Primary Hepatocytes (HP2 Heps) provide an ideal culture model for drug testing and drug development. HP2 10 Human Pooled Primary Hepatocytes contain cryopreserved hepatocytes pooled from 10 different donors and have undergone only one freeze cycle. Pooled hepatocytes provide the genetic diversity necessary for superior reliability and predictability of the metabolic characteristics of a test compound relative to a representative population. Pooled hepatocytes increase experimental control and reduce costs by eliminating the need to conduct redundant experiments necessary to obtain population-based data. Each lot has undergone a single freeze cycle, assuring maximum hepatocyte viability and consistency from donor to donor within the pool. Cell Features: Each donor's hepatocytes have been cryopreserved ONCE immediately after isolation and purification. Pools of 10 or 20 donors are available. Each donor is represented by a statistically significant number of cells relative to the pool. There is extensive quality control providing characterization of viability and enzyme activity from both individual donors and the total pool. AcceGen guarantees performance and quality. Donor information is available.

聲明：產(chǎn)品僅供科研使用